NAVERIS is a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers.

NAVERIS' mission is to improve outcomes for the millions of people at risk of developing viral cancers through novel molecular diagnostics that enable earlier cancer detection. 

NAVERIS was founded in 2017 by Piyush B. Gupta and Philip Haydon. The company is headquartered in Natick, Massachusetts, with an office in North Carolina.

Naveris’ blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.

Naveris’ lead product, NavDx®, applies proprietary technology to enable ultrasensitive detection of HPV-related cancer. Naveris currently provides the NavDx® test through its CLIA laboratory to cancer centers throughout the U.S.

NAVERIS has more than 25 medical institutions who have partnered with the company to conduct clinical studies and trials utilizing its technology. The company has also partnered with biotechnology companies developing immunotherapies for HPV-related cancers.

NAVERIS is backed by Gurnet Point Capital (GPC), TechU Ventures, BrightEdge, and others. The company raised an additional $33.4M on Sep 19, 2022. This is an extension of its previous $19M Series A in Dec 2020. This brings the total funding raised by NAVERIS to $52.4M to date.